Torsten M. Madsen, MD, PhD

CEO

Torsten earned his MD and PhD from Copenhagen University. After a postdoctoral stay at the Molecular Psychiatry Lab at Yale Medical School and clinical training in psychiatry he continued his career in clinical drug development. He has been responsible for development programs in multiple indications, spanning all phases of drug development. He has international leadership experience in biotech and the pharmaceutical industry, both from public and privately held companies.

Kenneth A Petersen, MD, PhD

COO and Founder

After earning his MD at Copenhagen University, Kenneth trained at Academic Hosiptals in General medicine, Pediatrics and Neurology.

He has also earned a Ph.d in neuroscience from Copenhagen Univeristy. He has worked in both biotech and large pharma with clinical drug development from early to late phase studies and in business development.  He founded Hoba Therapeutics in 2017 with seed investment from Novo Holdings and Borean Innovation

John Kemp, PhD

CSO

John was most recently CSO at Syndesi Therapeutics, which was acquired by Abbvie in March 2022 in a USD 1 B deal. He brings 30 years of experience in CNS drug discovery and development He previously held positions as Chief R&D Officer at Evotec, head of CNS research at Roche, and Senior Director, Neuroscience Discovery at Janssen. John has published over 140 peer-reviewed articles.

Mikkel Dybkjaer, MSc Econ

CFO

Mikkel has an MSc in Economics from Copenhagen University.

He has over 20 years of extensive experience in corporate finance, strategy, and business development from positions at IO Biotech, H. Lundbeck, and Genmab. He participated in several large licensing deals and funding rounds. He participated in the IPO of IO Biotech at Nasdaq Global Markets in November 2021.

E-mail: md@hobatherapeutics.com

Amanda has 20 years of biopharmaceutical experience, specifically  in venture capital, portofolio management, business development and business development. Most recently, she served as Managing Director of venture investments for Conneticut Innovations. She also played a significant role in founding and growing multiple companies.

Amanda earned her PhD in Cell Biology and Anatomy at Texas Tech Univeristy Healthy Science Center. She was also a post doc fellow at Yale University

Morten joined Novo Holdings in 2016 and serves as Partner in the company creation team of Novo Seeds where he leads new company formation. He serves on the Board of Acesion Pharma, Avilex, Camels IDS, NMD Pharma, STipe Therapeutics, and Syndesi Therapeutics. Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A, corporate strategy, BD&L, portfolio management and equity investments. While at Lundbeck Morten successfully led the acquisition of orphan neurology company Chelsea Therapeutics for 658 USD m and was involved in a range of other deals including the 1.8 USD Bn alliance with Otsuka Pharmaceuticals as well as equity investments and spinouts. Before Lundbeck, Morten worked as commercial manager in technology transfer to commercialize and establish new companies in biotech. Earlier in his career, Morten co-led the life science consulting practice at a boutique advisory firm focusing on business development and management consulting. Morten holds an MSc in Human Biology from the University of Copenhagen.

Teit is an experienced life science executive with a strong research background. Today Teit serves as Senior Vice President in ALK A/S with the responsibility for drug discovery and the early phases of product development. Prior to his position at ALK, Teit served as CEO and President for 13 years in the biotech company (NsGene A/S) that he founded as a spin-off from NeuroSearch A/S in 1999. During his time as CEO of NsGene, Teit build and maintained a competitive R&D organization and secured more than DKK 400 million in cash to support the NsGene business.

Teit holds a Ph.D. in Molecular Biology and before appearing on the Biotech/pharma scene, Teit had an academic career that culminated with a position as Assistant Professor at Johns Hopkins University in Baltimore, US

Camilla joined the board of Hoba Therapeutics in 2021. She brings more than a decade of international business development experience from early academic start-up to industry. Camilla is currently a principal at Novo Holdings, where she is responsible for company creation and early investments, in addition to investments through the REPAIR Impact fund. Camilla also serves as an observer on the Board of Directors of Muna, Hemab and Acesion. Camilla has a PhD in Medicinal Chemistry and a Master of Pharmacy degree from Copenhagen University.

Nina is a venture investor at Vækstfonden (The Danish Growth Fund). She joined Hoba as a board observer in 2022 and has over 15 years of strategy, portfolio management, and business development experience from life science multinationals across the US, Germany, and Denmark. Nina is an American national and holds an MBA from Harvard Business School and B.Sc. in Biomedical Engineering from Johns Hopkins University.